Literature mining in support of drug discovery

The drug discovery enterprise provides strong drivers for data integration The drug discovery enterprise provides strong drivers for data integration.While attention in this arena has tended to focus on integration of primary data from omics and other large platform technologies contributing to drug discovery and development, the scientific literature remains a major source of information valuable to pharmaceutical enterprises, and therefore tools for mining such data and integrating it with other sources are of vital interest and economic impact.

Pankaj Agarwal, Director, Systematic Drug Repositioning, Computational Biology, GlaxoSmithKline kindly provided this whitepaper that provides a brief overview of approaches to literaturemining as they relate to drug discovery, and offers an illustrative case study of a ‘lightweight' approach we have implemented within an industrial context.

Download the whitepaper here for more information

Drug discovery will also be discussed at the World Drug Repositioning Congress USA. If a key issue of your business right now is pipeline building and grasping the potential from repositioned drugs then you must attend!

Download the brochure for more information

Leave a Reply

Your email address will not be published. Required fields are marked *